No Benefit With Longer Course of ADT in Localized, High-Risk Prostate Cancer
A longer course of androgen deprivation therapy does not improve outcomes in patients with localized, high-risk prostate cancer receiving I-125 brachytherapy and external beam radiotherapy, a phase 3 trial suggests.